Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2009

View Archived Issues

4SC commences phase II 4SC-201 trial in hepatocellular carcinoma

Sitaxsentan treatment has multiple benefits in chronic kidney disease

Pfizer develops novel irreversible and reversible SARS 3CL protease inhibitors

Tumor hypoxia marker [18F]HX4 safe in phase I trial, phase II study planned

Novavax reports preclinical results from ferret study of H1N1 influenza VLP vaccine

Lpath completes enrollment in phase I study of iSonep in wet AMD

Roche reports results for first half 2009

GlaxoSmithKline claims tricyclic nitrogen-containing compounds as antibacterials

Array BioPharma describes Akt protein kinase inhibitors for cancer

Cathepsin K inhibitors identified at Amura for treating bone disorders

Solvay discloses bifeprunox derivatives for PD and other CNS-related disorders

LXR ligands for a variety of potential applications described by Wyeth

Abbott discloses new calpain inhibitors for neurological and other disorders

Focus of gamma-secretase inhibitor PF-3084014 shifts to cancer

Bristol-Myers Squibb identifies potent corticotropin-releasing factor-1 receptor antagonist

Light Sciences Oncology treats patients in phase II Aptocine trial in BPH

Peplin completes enrollment in final phase III ingenol mebutate trial in AK

COTI-2 plus Doxil superior to Doxil alone in animal ovarian cancer model

Amira submits IND for AM-461

Ablynx reports phase I results for subcutaneous administration of ALX-0681

Forest reports phase IIb results for oglemilast in COPD

Pfizer targets the type 1 glycine transporter with PF-3463275 for schizophrenia

Severe lung damage linked to long-term occupational nanoparticle exposure

InterMune and Roche initiate dosing in phase IIb clinical trial of ITMN-191

Gentium reports results from phase III defibrotide trial for sVOD

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...